Dechra boosts trade in second half - graduate jobs

Graduates hoping to enter the medicine industry will be interested to learn that pets drugs firm Dechra Pharmaceuticals has reported that trading was stronger for the six months to the end of 2010 than the previous year.

The group attributed the strong performance, with revenues up 4%, to the acquisitions of DermaPet and Genitrix and stronger European and US trading, with these revenues up 5.6% and 18.7% respectively on 2009.

Revenues from Florida-based DermaPet and the rise in Vetoryl sales offset the previously reported supply issues with ophthalmic and otic products, according to the group.

A statement from the company said: "The trading performance of the group has continued to be resilient in testing economic conditions.

"The two acquisitions made during the period are in line with our strategy to develop our international veterinary pharmaceuticals business. They have increased the group's product portfolio, particularly in the US where, on the strength of the DermaPet acquisition, we have been able to significantly increase our sales and marketing capability.

"The board remains confident the group will continue to make positive progress throughout the remainder of the financial year."